Лечение синдрома сухого глаза, комплексный подход
Ключевые слова:
сухой глаз, роговица, глазная поверхность, питаниеАннотация
Синдром сухого глаза (ССГ) представляет собой хроническое состояние глазной поверхности, характеризующееся неспособностью вырабатывать достаточное количество или оптимальное качество слезы для увлажнения глаз. Во всем
мире при начальном лечении ССГ применяются искусственные заменители слезы, однако они не устраняют основные причины заболевания. В целом, современные методы лечения либо уменьшают воспаление поверхности глаза,
либо стабилизируют слезную пленку, тем не менее все еще не ясно, какая терапия лучше для тех, у кого ССГ связан
с дефицитом слезы или является следствием аномально быстрого испарения. ССГ относится к спектру хронических
воспалительных заболеваний, следовательно, изменение образа жизни, оценка и коррекция питания, наряду с приемом лекарств, направленных на уменьшение воспаления, могут быть эффективной стратегией. «Целостный», персонализированный подход может дать начало новому поколению клинических исследований, которые позволят получить более эффективные решения для лечения ССГ.
Библиографические ссылки
1. Tsubota K, Yokoi N, Shimazaki J, et al. Asia Dry Eye Society. New Perspectives on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society. Ocul Surf. 2017;15(1):65-76. doi: 10.1016/j.jtos.2016.09.003
2. Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. The Ocular Surface. 2017;5(3):269–275. doi: 10.1016/j. jtos.2017.05.005
3. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Deutsches Ärzteblatt International. 2015;112(5):71– 82. doi: 10.3238/arztebl.2015.0071
4. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. The Ocular Surface. 2017;15(3):334–365. doi: 10.1016/j. jtos.2017.05.003
5. Sullivan DA, Rocha EM, Aragona P, et al. (TFOS DEWS II sex, gender, and hormones report. The Ocular Surface. 2017;15(3):284–333. doi:10.1016/j.jtos.2017.04.001
6. Rouen P, White M. Dry Eye Disease: Prevalence, Assessment, and Management. Home Healthcare Now. 2018;36(2):74–83. doi: 10.1097/NHH.0000000000000652
7. Milner MS, Beckman KA, Luchs JI, et al. Dysfunctional tear syndrome: Dry eye disease and associated tear film disorders— New strategies for diagnosis and treatment. Current Opinion in Ophthalmology. 2017;27(1):3–47. doi: 10.1097/01. icu.0000512373.81749.b7
8. Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. The Ocular Surface. 2017;15(3): 511–538. doi: 10.1016/j. jtos.2017.05.004
9. Ekker MS, Janssen S, Seppi K, et al. Ocular and visual disorders in Parkinson’s disease: Common but frequently overlooked. Parkinsonism and Related Disorders. 2017;40:1–10. doi: 10.1016/j.parkreldis.2017.02.014
10. AlAwlaqi A, Hammadeh M. Examining the relationship between hormone therapy and dry-eye syndrome in postmenopausal women: A cross-sectional comparison study. Menopause. 2016;23(5):550–555. doi: 10.1097/GME.0000000000000570
11. Sriprasert I, Warren DW, Mircheff AK, et al. Dry eye in postmenopausal women: a hormonal disorder. Menopause. 2016;23(3):343-51. doi: 10.1097/GME.0000000000000530
12. American Academy of Ophthalmology Cornea/External Disease PanelPreferred Practice Pattern Guidelines. Dry Eye Syndrome. San Francisco, CA: American Academy of Ophthalmology. 2013; Retrieved from http://www.aao.org/ppp
13. Downie LE, Keller P. RA pragmatic approach to dry eye diagnosis: Evidence into practice. Optometry and Vision Science. 2015;92(12):1189 1197. doi: 10.1097/OPX.0000000000000721
14. Guzman M, Keitelman I, Sabbione F, et al. Desiccating Stress- Induced Disruption of Ocular Surface Immune Tolerance Drives Dry Eye Disease. Clin. Exp. Immunol. 2016;184:248–256. doi: 10.1111/cei.12759. Epub 2016 Feb 15
15. Stern ME, Schaumburg CS, Pflugfelder SC. Dry Eye as a Mucosal Autoimmune Disease. Int. Rev. Immunol. 2013;32:19–41. doi: 10.3109/08830185.2012.748052
16. Holland EJ, Darvish M, Nichols KK, et al. Efficacy of Topical Ophthalmic Drugs in the Treatment of Dry Eye Disease: A Systematic Literature Review. Ocul. Surf. 2019;17(3):412–423. doi: 10.1016/j.jtos.2019.02.012
17. Wladis EJ, Bradley EA, Bilyk JR, et al. Oral Antibiotics for Meibomian Gland-Related Ocular Surface Disease: A Report by the American Academy of Ophthalmology. Ophthalmology. 2016;123:492–496. doi: 10.1016/j.ophtha.2015.10.062
18. Nebbioso M, Fameli V, Gharbiya M, et al. Investigational drugs in dry eye disease. Expert OpinInvestig Drugs. 2016;25:1437–1446. doi: 10.1080/13543784.2016.1249564
19. Sridhar MS. Anatomy of cornea and ocular surface. Indian J Ophthalmol. 2018;66(2):190–194. doi: 10.4103/ijo.IJO_646_17
20. Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLA O J. 2015;21:221–235.
21. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocular Surface 2004;2:149.
22. McCulley JP, Shine WE. Meibomian gland function and the tear lipid layer. Ocular Surface. 2003;1:97.
23. Johnson ME, Murphy PlJ. Changes in the tear film and ocular surface from dry eye syndrome,Progress in Retinal and Eye Research. 2004;23(4):449-474.
24. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966:211–22. doi: 10.1111/j.1749-6632.2002. tb04217.x
25. Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Ret Eye Res. 2004;23:449- 474. doi: 10.1016/j.preteyeres.2004.04.003
26. Carney LG, Hill RM. Human tear pH. Diurnal variations. Arch Ophthalmol. 1976;94(5):821-824. doi: 10.1001/ archopht.1976.03910030405011
27. Bachman WG, Wilson G. Essential ions for maintenance of the corneal epithelial surface. Invest Ophthalmol Vis Sci. 1985;26:1484–1488.
28. Gachon AM, Verrelle P, Betail G, et al Immunological and electrophoretic studies of human tear proteins. Exp Eye Res. 1979;29(5):539–553. doi: 10.1016/0014-4835(79)90154-4
29. Schultz G, Khaw PT, Oxford K, et al. Growth factors and ocular wound healing. Eye.1994;8:184–187. doi: 10.1038/eye.1994.43
30. Davidson HJ, Kuonen VJ. The tear film and ocular mucins. Vet Ophthalmol. 2004;7:71–77. doi: 10.1111/j.1463- 5224.2004.00325.x
31. Gipson IK, Spurr-Michaud S, Argueso P, et al. Mucin Gene Expression in Immortalized Human Corneal–Limbal and Conjunctival Epithelial Cell Lines. Invest. Ophthalmol. Vis. Sci. 2003;44(6):2496-2506. doi: 10.1167/iovs.02-0851
32. Malekahmadi M, Farrahi F, Tajdini A. Serum Vitamin A Levels in Patients with Chalazion. Med Hypothesis Discov Innov Ophthalmol. 2017;6(3):63–66.
33. Kymionis G, Naoumidi T, Aslanides I, et al. Corneal Iron Ring After Conductive Keratoplasty. Am J Ophthalmol. 2003;136(2):378– 379. doi: 10.1016/s0002-9394(03)00224-1
34. Riordan-Eva P, Whitcher J. Vaughan & Asbury’s General Ophthalmology. (17th ed). 2007.
35. Steinberg E, Wilson LA, Waring 3rd GO, et al. Stellate iron lines in the corneal epithelium after radial keratotomy. Am J Ophthalmol. 1984;98(4):416–421. doi: 10.1016/0002-9394(84)90122-3
36. Koenig SB, McDonald MB, Yamaguchi T, et al. Corneal iron lines after refractive keratoplasty. ArchOphthalmol. 1983;101(12):1862-5. doi: 10.1001/archopht.1983.01040020864004
37. Assil K, Quantock AJ, Barrett AM, et al. Corneal iron lines associated with the intrastromal corneal ring. Am J Ophthalmol. 1993;116(3):350 365. doi: 10.1016/s0002-9394(14)71353-4
38. Loh A, Hadziahmetovic M, Dunaief JL. Iron homeostasis and eye disease. Biochim Biophys Acta. 2009;1790(7):637–649. doi: 10.1016/j.bbagen.2008.11.001
39. Graham JE, Moore JE, Jiru X, et al. Ocular Pathogen or Commensal: A PCR-Based Study of Surface Bacterial Flora in Normal and Dry Eyes. Investig. Ophthalmol. Vis. Sci. 2007;48:5616–5623. doi: 10.1167/iovs.07-0588
40. Otto M. Staphylococcus Epidermidis — The ‘Accidental’ Pathogen. Nat. Rev. Microbiol. 2009;7:555. doi: 10.1038/nrmicro2182
41. Fukushima K, Sasaki I, Ogawa H, et al. Colonization of Microflora in Mice: Mucosal Defense Against Luminal Bacteria. J. Gastroenterol. 1999;34:54–60. doi: 10.1007/s005350050216
42. Koropatkin NM, Cameron EA, Martens EC. How Glycan Metabolism Shapes the Human Gut Microbiota. Nat. Rev. Microbiol. 2012;10:323. doi: 10.1038/nrmicro2746
43. Lu LJ, Liu J. Human Microbiota and Ophthalmic Disease. Yale J. Biol. Med. 2016;89:325–330.
44. Feher J, Pinter E, Kovács I, et al. Irritable eye syndrome: neuroimmune mechanisms and benefits of selected nutrients. Ocul Surf. 2014;12(2):134–145. doi: 10.1016/j.jtos.2013.09.002
45. Steven P, Schwab S, Kiesewetter A, et al. Disease-Specific Expression of Conjunctiva Associated Lymphoid Tissue (CALT) in Mouse Models of Dry Eye Disease and Ocular Allergy. Int J Mol Sci. 2020;21(20):7514. doi: 10.3390/ijms21207514
46. Schmidl D, Schmetterer L, Witkowska KJ, et al. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Cornea. 2015;34(4):421–426. doi: 10.1097/ ICO.0000000000000358
47. Sullivan DA, Wickham LA, Rocha EM, et al. Androgens and dry eye in Sjögren’s syndrome. Ann N Y Acad Sci. 1999;22;876:312–324. doi: 10.1111/j.1749-6632.1999.tb07656.x
48. Chisari G, Rampello L, Chisari E, et al. Microbiology Synergism Between Tear Substitutes and Symbiotic Treatment of Patients with Irritable Bowel Syndrome. Acta Med. Mediterr. 2016;32:463.
49. Kawashima M, Nakamura S, Izuta Y, et al. Dietary Supplementation with a Combination of Lactoferrin, Fish Oil, and Enterococcus faecium WB2000 for Treating Dry Eye: A Rat Model and Human Clinical Study. Ocul. Surf. 2016;14:255–263. doi: 10.1016/j. jtos.2015.12.005
50. Kim J, Choi HS, Kim JY, et al. Clinical Effect of IRT-5 Probiotics on Immune Modulation of Autoimmunity or Alloimmunity in the Eye. Nutrients. 2017;9:1166. doi: 10.3390/nu9111166
51. De Paiva CS, Jones DB, Stern ME, et al. Altered Mucosal Microbiome Diversity and Disease Severity in Sjögren Syndrome. Sci. Rep. 2016;6:23561. doi: 10.1038/srep23561
